GENEREX BIOTECHNOLOGY CORP: 10-K filed 2018-10-26
What GENEREX BIOTECHNOLOGY CORP reported in its annual report filed 2018-10-26 (fiscal FY 2018): 35 published measures, 72 facts as tagged in accession 0001607062-18-000361.
This filing
- Form
- 10-K (annual report)
- Filed
- 2018-10-26
- Fiscal period
- fiscal FY 2018
- Accession
- 0001607062-18-000361 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GENEREX BIOTECHNOLOGY CORP filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 6,606,854 | USD | |
| At 2017-07-31 | 10,094,545 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 50,191,522 | USD | |
| At 2017-07-31 | 89,970,776 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | -43,584,668 | USD | |
| At 2017-07-31 | -79,876,231 | USD | |
| At 2016-07-31 | -11,216,850 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 1,046,365 | USD | |
| At 2017-07-31 | 2,879,165 | USD | |
| At 2016-07-31 | 16,899 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 35,948,698 | USD | 365 |
| 2016-08-01 to 2017-07-31 | -76,832,599 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | -2,293,214 | USD | 365 |
| 2016-08-01 to 2017-07-31 | -1,170,349 | USD | 365 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 703,244 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 453,694 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 4,035,949 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | -8,552 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 12,363 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 410,000,000 | USD | |
| At 2017-07-31 | 446,000,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 1,068,101 | shares | 365 |
| 2016-08-01 to 2017-07-31 | 987,288 | shares | 365 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 2,591,129 | shares | 365 |
| 2016-08-01 to 2017-07-31 | 987,288 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 34.02 | USD/shares | 365 |
| 2016-08-01 to 2017-07-31 | -70.92 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 14.02 | USD/shares | 365 |
| 2016-08-01 to 2017-07-31 | -70.92 | USD/shares | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 31,536 | USD | |
| At 2017-07-31 | 573 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | -2,495,609 | USD | 365 |
| 2016-08-01 to 2017-07-31 | -1,596,841 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 1,188,246 | USD | |
| At 2017-07-31 | 2,911,091 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 583,594 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 743,101 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 25,229,015 | USD | |
| At 2017-07-31 | 23,910,750 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-01-18 | 14,300,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 23,280 | USD | |
| At 2017-07-31 | 25,851 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 3,198,853 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 1,596,841 | USD | 365 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 12,075 | USD | |
| At 2017-07-31 | 10,035 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 839,147 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 422,294 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 1,068,101 | shares | |
| At 2017-07-31 | 1,068,101 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 798,422 | USD | |
| At 2017-07-31 | 783,150 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 145,658 | USD | |
| At 2017-07-31 | 123,876 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-07-31 | 3,187,757 | USD | |
| At 2017-12-28 | 276,380 | USD | |
| At 2017-07-31 | 2,911,377 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 36,334,098 | USD | 365 |
| 2016-08-01 to 2017-07-31 | -70,016,194 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 2,359,706 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 1,174,547 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 21,782 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 3,675 | USD | 365 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 23,780 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 5,045 | USD | 365 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | 2,571 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 1,370 | USD | 365 |
| 2015-08-01 to 2016-07-31 | 1,370 | USD | 366 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | -33,555 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 980 | USD | 365 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-08-01 to 2018-07-31 | -2,040 | USD | 365 |
| 2016-08-01 to 2017-07-31 | 11,106 | USD | 365 |
Inspect the source
- Entity
- GENEREX BIOTECHNOLOGY CORP / CIK 0001059784
- Captured
- SEC response SHA-256
a8779b8c3aa8286320834b30d50af09999238cecacb9e7883d21e11477763a4d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001059784.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))